Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands.
Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004.
The need for an effective vaccine to prevent the global spread of human immunodeficiency virus type 1 (HIV-1) is well recognized. Passive immunization and challenge studies in non-human primates testify that broadly neutralizing antibodies (BrNAbs) can accomplish protection against infection. In recent years, the introduction of new techniques has facilitated the discovery of an unprecedented number of new human BrNAbs that target and delineate diverse conserved epitopes on the envelope glycoprotein spike (Env). The epitopes of these BrNAbs can serve as templates for immunogen design aimed to induce similar antibodies. Here we will review the characteristics of the different classes of BrNAbs and their target epitopes, as well as factors associated with their development and implications for vaccine design.
人们普遍认识到，需要有一种有效的疫苗来预防人类免疫缺陷病毒 1 型（HIV-1）在全球范围内的传播。在非人类灵长类动物中的被动免疫和挑战研究证明，广泛中和抗体（BrNAb）可以实现对感染的保护。近年来，新技术的引入促进了大量新的人类 BrNAb 的发现，这些 BrNAb 针对并描绘了包膜糖蛋白刺突（Env）上不同的保守表位。这些 BrNAb 的表位可以作为免疫原设计的模板，旨在诱导类似的抗体。在这里，我们将回顾不同类别 BrNAb 的特征及其靶表位，以及与它们的发展相关的因素及其对疫苗设计的影响。
Zotero 插件